Komori
S

Soiken Holdings Inc.

2385Information and Communications, Services and OthersMicro cap
220JPY+0.5%
★ Watch (sign-up required)
Price history
¥220Latest-37.5%
Drag across the chart to measure the move between two points.Delayed 15 minutes · monthly closing basis
Business overview

The Group is a corporate group whose core business is biological assessment systems, with healthcare support, cosmetics, health supplements, and functional materials development as its principal businesses. From the fiscal year ending June 2027, it will reorganize its reporting segments into three categories: Biological Assessment Systems, Corporate Healthcare Support, and Healthcare Platform. The cosmetics, health supplements, and functional materials development businesses will be integrated into 日本予防医薬㈱. Overall, the Group plans to build and apply evidence based on university-developed biomarker technologies, promote the development of a comprehensive healthcare platform leveraging medical DX, expand overseas operations with a focus on China and ASEAN, and use M&A and business alliances to expand its business scope and improve capital efficiency.

Recurring subjects
No threads yetThis company's filings have not been read yet. We are adding them progressively.
Companies sharing a theme
Loading
Documents
See all timely disclosuresSee all statutory filings
News
See all news
Key numbersShowing 8 of 20
PER
27.15How many years of earnings it would take to buy the stock. The market average is generally considered to be around 15.
PBR
0.94How many times the company's net assets? Around 1x is generally considered a benchmark.
ROE
3.5%Earning power. A figure above 10% is generally considered good.
Dividend yield
0.0%The annual dividend as a percentage of the share price.
Market capitalization
¥5.8bnShare price × number of shares. The value of the entire company.
Equity ratio
89.2%The proportion of assets funded by money that does not have to be repaid.
Operating margin
7.1%The percentage of revenue remaining from the company’s core business.
Revenue growth (3 years)
-21.8%The average annual growth in sales over the past three years.
What to watch next
報告セグメント再編（化粧品/健康補助食品/機能性素材開発の統合を含む）と、2027年6月期以降の「ヘルスケアプラットフォーム事業」本格展開
2027年6月期以降（進捗は今後の四半期で確認）Impact HighLikelihood Medium
構造改革（固定費削減・広告/販促効率化）による営業利益率の維持・改善
次の決算期（24-36か月のレンジで継続確認）Impact MediumLikelihood Medium
規制・薬事/広告審査体制の整備が進み、オンライン診療・オンライン薬局等の提供品質/継続性が高まる
2026年以降、運用KPIが出るタイミングImpact MediumLikelihood Low
What to watch next
Loading
Who owns itTop holders total 45.7%
Listed holders 45.7%Everyone else 54.3%
GOLONG HOLDING CO., LIMITED17.68%
Kajimoto Osami (梶本 修身)16.92%
光通信KK投資事業有限責任組合3.45%
細川 陽介1.76%
天野 謙二郎1.35%
山下 敬弘1.22%
INTERACTIVE BROKERS LLC0.90%
市川 敏夫0.86%
2 other listed holders1.52%
Who owns it
HolderOwnership (%)
GOLONG HOLDING CO., LIMITED17.68
Kajimoto Osami (梶本 修身)16.92
光通信KK投資事業有限責任組合3.45
細川 陽介1.76
天野 謙二郎1.35
山下 敬弘1.22
INTERACTIVE BROKERS LLC0.90
市川 敏夫0.86
2 other listed holders1.52
This company's documents
Filings
Timely disclosures
Threads